952 related articles for article (PubMed ID: 21982571)
1. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
Okarvi SM; Jammaz IA
Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782
[TBL] [Abstract][Full Text] [Related]
3. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
Fragogeorgi EA; Zikos C; Gourni E; Bouziotis P; Paravatou-Petsotas M; Loudos G; Mitsokapas N; Xanthopoulos S; Mavri-Vavayanni M; Livaniou E; Varvarigou AD; Archimandritis SC
Bioconjug Chem; 2009 May; 20(5):856-67. PubMed ID: 19344122
[TBL] [Abstract][Full Text] [Related]
4. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
5. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model.
Ananias HJ; Yu Z; Dierckx RA; van der Wiele C; Helfrich W; Wang F; Yan Y; Chen X; de Jong IJ; Elsinga PH
Mol Pharm; 2011 Aug; 8(4):1165-73. PubMed ID: 21699202
[TBL] [Abstract][Full Text] [Related]
6. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core.
García Garayoa E; Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwe DA; Schibli R; Schubiger PA
Bioconjug Chem; 2008 Dec; 19(12):2409-16. PubMed ID: 18998719
[TBL] [Abstract][Full Text] [Related]
7. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwé DA; Schubiger PA; Schibli R; García Garayoa E
Bioconjug Chem; 2008 Dec; 19(12):2432-9. PubMed ID: 19053304
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.
Rogers BE; Manna DD; Safavy A
Cancer Biother Radiopharm; 2004 Feb; 19(1):25-34. PubMed ID: 15068608
[TBL] [Abstract][Full Text] [Related]
9. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
10. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
Lin KS; Luu A; Baidoo KE; Hashemzadeh-Gargari H; Chen MK; Pili R; Pomper M; Carducci M; Wagner HN
Bioconjug Chem; 2004; 15(6):1416-23. PubMed ID: 15546210
[TBL] [Abstract][Full Text] [Related]
11. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation.
Marsouvanidis PJ; Maina T; Sallegger W; Krenning EP; de Jong M; Nock BA
J Nucl Med; 2013 Oct; 54(10):1797-803. PubMed ID: 24009275
[TBL] [Abstract][Full Text] [Related]
12. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.
Däpp S; Müller C; Garayoa EG; Bläuenstein P; Maes V; Brans L; Tourwé DA; Schibli R
EJNMMI Res; 2012 Jun; 2(1):24. PubMed ID: 22681935
[TBL] [Abstract][Full Text] [Related]
13. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
[TBL] [Abstract][Full Text] [Related]
15. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
17. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.
Smith CJ; Gali H; Sieckman GL; Higginbotham C; Volkert WA; Hoffman TJ
Bioconjug Chem; 2003; 14(1):93-102. PubMed ID: 12526698
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.
Jiménez-Mancilla N; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Isaac-Olivé K; Camacho-López M; Torres-García E
J Labelled Comp Radiopharm; 2013 Nov; 56(13):663-71. PubMed ID: 25196028
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
